Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Fulcrum Therapeutics (FULC) to $24 from $15 and keeps an Overweight rating on the shares. The updated pociredir data are encouraging, but it is still early, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics price target raised to $10 from $7 at RBC Capital
- Fulcrum Therapeutics Reports Positive Phase 1b Trial Results
- Fulcrum Therapeutics price target raised to $23 from $16 at Piper Sandler
- Fulcrum Therapeutics price target raised to $25 from $18 at H.C. Wainwright
- Fulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial